Heart Failure/Transplantation
2ry analysis of a RCT | Decongestion with acetazolamide in acute heart failure across the spectrum of left ventricular EF.
25 Nov, 2022 | 12:45h | UTCOriginal Study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
Commentary on Twitter
#OriginalResearch simpub #AHA2022 #CIRCAHA22: Acetazolamide added to loop diuretics ⬆️ likelihood of successful decongestion similarily in patients with HFrEF, HFmrEF and HFpEF. Data from the #ADVOR trial. @PieterMartensMD @WilfriedMullens #AHAJournals https://t.co/MkISN2H1vA pic.twitter.com/qFjCKdRaF6
— Circulation (@CircAHA) November 6, 2022
RCT | Impact of empagliflozin on decongestion in acute heart failure.
23 Nov, 2022 | 14:04h | UTCCommentary: Empagliflozin in Patients Hospitalized for Acute Heart Failure – EMPULSE – American College of Cardiology
Commentary on Twitter
What's the impact of empagliflozin on decongestion in acute heart failure? New insights from the EMPULSE trial in EHJ!https://t.co/O1MZTFPWCc#SGLT2 #decongestion #heartfailure #empagliflozin #cardiotwitter @escardio @ESC_Journals pic.twitter.com/QLJYNgl1Zo
— EHJ Editor-in-Chief (@ehj_ed) October 19, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Cohort Study | Prognostic prediction of genotype vs. phenotype in genetic cardiomyopathies.
23 Nov, 2022 | 13:57h | UTC
Commentary on Twitter
We are out with our last big work on the importance of genotype for the prognostic stratification of Cardiomyopathies! @CardiologyASUGI @Trieste_Denver @JACCJournals @PaldinoAlessia https://t.co/82byVNnUhK pic.twitter.com/KYoxDXkzr6
— matteo dal ferro (@matteodalferro) November 17, 2022
Under a Creative Commons license
Right heart failure in the ED: approach to diagnosis and management.
23 Nov, 2022 | 13:54h | UTCRight Heart Failure in the ED: Approach to Diagnosis and Management – emDocs
RCT | Influenza vaccine to reduce adverse vascular events in patients with heart failure.
18 Nov, 2022 | 13:26h | UTCCommentary:
Flu vaccines cut pneumonia, cardiovascular issues in heart failure patients – CIDRAP
Flu Shot Could Be Lifesaver for Folks With Heart Failure – HealthDay
M-A | Effect of pharmacological treatment on outcomes of heart failure with preserved ejection fraction.
18 Nov, 2022 | 13:14h | UTC
RCT | Early routine use of ECMO fails to improve outcomes in patients with cardiogenic shock.
11 Nov, 2022 | 14:01h | UTCCommentaries:
Early ECMO No Better Than Watch-and-Wait Approach in Cardiogenic Shock – TCTMD
Immediate Use of ECMO Did Not Improve Outcomes in Patients with Cardiogenic Shock – HCP Live
Commentary on Twitter
#OriginalResearch simpub #AHA2022: In this #RCT immediate implementation of VA-ECMO in patients with cardiogenic shock did not improve clinical outcomes compared with an early conservative strategy which allowed downstream use of… #CIRCAHA22 #AHAJournals https://t.co/03qVyC0Vgl pic.twitter.com/WRNDsAZfpD
— Circulation (@CircAHA) November 6, 2022
RCT | Using an algorithm to stratify the risk of patients with acute heart failure may improve outcomes.
9 Nov, 2022 | 12:30h | UTCTrial of an Intervention to Improve Acute Heart Failure Outcomes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: New Tool Assesses Risk in Acute HF Then Suggests Next Steps, Cutting Later Events – TCTMD
Commentary on Twitter
The use of a validated tool for risk assessment, combined with rapid follow-up, led to a lower risk of death or hospitalization for cardiovascular causes at 30 days among patients with acute heart failure. #AHA22 https://t.co/0cbvcHl3US pic.twitter.com/kpWbRGpOJX
— NEJM (@NEJM) November 5, 2022
RCT | Rapid up-titration of guideline-directed medical therapies for acute heart failure reduced readmissions and deaths.
8 Nov, 2022 | 12:24h | UTCSafety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial – The Lancet (free registration required)
News Release: Maximizing heart failure meds within 2 weeks reduced risk of hospital readmission, death – American Heart Association
Commentary: STRONG-HF: Rapid Uptitration of GDMT After Acute HF Pays Dividends – TCTMD
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022
RCT | Intravenous iron did not significantly reduce hospital admissions in patients with heart failure and iron deficiency.
7 Nov, 2022 | 12:48h | UTCCommentaries:
IRONMAN Misses but Lends Support to IV Iron Repletion in HF – TCTMD
Review | Optimal perfusion targets in cardiogenic shock.
31 Oct, 2022 | 13:45h | UTCOptimal Perfusion Targets in Cardiogenic Shock – JACC: Advances
Commentary on Twitter
#CardiogenicShock (CS) carries marked morbidity and mortality, w/ limited data to guide hemodynamic targets. Randomized #clinicaltrials in CS subsets are necessary to better elucidate optimal #perfusion targets. https://t.co/XpmXmlMdww#JACCAdvances #resuscitation #CardioTwitter pic.twitter.com/VWDEYkQ3nm
— JACC Journals (@JACCJournals) July 4, 2022
Evolving presentation of cardiogenic shock: a review of the medical literature and current practices.
31 Oct, 2022 | 13:46h | UTC
Commentary on Twitter
#CardiogenicShock remains a leading cause of morbidity and mortality among patients with #CardiovascularDisease. In his review, authors sought to survey the medical literature and provide an update on current practice. Read this in full here: https://t.co/lA0Hj9PWaM pic.twitter.com/Vz63n5pWfL
— Cardiology and Therapy (@Cardio_Therapy) August 8, 2022
Cohort Study | Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation.
31 Oct, 2022 | 13:42h | UTC
Commentary on Twitter
New study shows that a subset of HFrEF patients without atrial fibrillation have a stroke risk equivalent to that of patients with AF who are not anticoagulatedhttps://t.co/AXM5ut2SUV#stroke #heartfailure #HF #cardiotwitter @ESC_Journals @escardio pic.twitter.com/Ppa17U79b8
— EHJ Editor-in-Chief (@ehj_ed) August 26, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license
Study commentary | From the management of altitude sickness to congestion in acute HF: a new season for acetazolamide?
27 Oct, 2022 | 12:27h | UTCFrom the management of altitude sickness to treatment of congestion in acute heart failure: a new season for acetazolamide? – European Heart Journal (free for a limited period)
Original study: RCT | Acetazolamide resulted in faster decongestion in patients with acute decompensated heart failure with volume overload.
Diaphragmatic function in cardiovascular disease: JACC review topic of the week.
25 Oct, 2022 | 13:22h | UTC
Review | Restrictive cardiomyopathy: definition and diagnosis.
24 Oct, 2022 | 13:58h | UTCRestrictive cardiomyopathy: definition and diagnosis – European Heart Journal
Commentary on Twitter
⚠️Great review 👉 Restrictive cardiomyopathy
📍definition
📍diagnosis
📍therapies available only for cardiac amyloidosis and, for iron overload cardiomyopath🆓📁 https://t.co/OtO7L45SBw pic.twitter.com/L55mPnmNtt
— Alfonso Valle (@ValleAlfonso) October 22, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ License
M-A | Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes.
19 Oct, 2022 | 14:11h | UTC
Position Statement | Use of biomarkers for the management of heart failure and acute coronary syndrome.
17 Oct, 2022 | 12:34h | UTC
A practical approach to the guideline-directed pharmacological treatment of heart failure with reduced ejection fraction.
17 Oct, 2022 | 12:15h | UTC
Review | Heart failure after right ventricular myocardial infarction.
14 Oct, 2022 | 14:05h | UTCHeart Failure After Right Ventricular Myocardial Infarction – Current Heart Failure Reports
Cohort Study | A collaborative home-based palliative care intervention for patients with heart failure reduced the risk of dying in the hospital.
13 Oct, 2022 | 13:37h | UTCCommentary: Home-Based Palliative Care for Heart Failure May Cut Risk for Dying in Hospital – HealthDay
Commentary on Twitter
Patients who received home-based, interdisciplinary palliative care were more likely to die at home than in hospital, compared to those who received usual care: https://t.co/JsLvANgcPK@kieranlquinn @PTanuseputro @sarina_isenberg #PalliativeCare #HeartFailure pic.twitter.com/6rOPtYQw2h
— CMAJ (@CMAJ) September 26, 2022
Extracorporeal membrane oxygenation for cardiogenic shock: a meta-analysis of mortality and complications.
11 Oct, 2022 | 13:33h | UTC
RCT | Riociguat improved hemodynamics but increased dropouts in pulmonary hypertension and HFpEF.
11 Oct, 2022 | 13:26h | UTC
Commentary on Twitter
Riociguat in pulmonary hypertension and heart failure with preserved ejection fraction: results of randomized, double-blind, placebo-controlled, multicentre trial out.https://t.co/FYmorikQR5#HFpEF #HF #cardiotwitter @ESC_Journals @escardio pic.twitter.com/4sSeYt7Adq
— EHJ Editor-in-Chief (@ehj_ed) October 7, 2022
Under a https://creativecommons.org/licenses/by-nc/4.0/ license